AbbVie Inc.
ABBV Healthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 290.4%, free cash flow fell 36.2% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
Follow ABBV
AbbVie Inc. 10-K filed Feb 20, 2026
What changed
Item 7, Management’s Discussion and Analysis, against the 10-K filed Feb 14, 2025: 39 added · 41 removed · 35 modified; 33 with only figures updated; 1 moved without change
115 more changes in this Item, word by word, in Powerpack.
Powerpack